J&J And India’s J.B. Chemicals On Collision Course As Sale Of Russian OTC Business Hits Snag
This article was originally published in PharmAsia News
Executive Summary
J&J’s sudden claim for funds from an escrow account has sparked speculation on the future of the deal with J.B. Chemicals.
You may also be interested in...
Back To Square One: India's J.B.Chemicals, Dr. Reddy's Terminate Russa Rx Deal
MUMBAI - Less than three months after agreeing to sell its Russia-CIS prescriptions business, Indian drug maker J.B. Chemicals & Pharmaceuticals Ltd. has called-off its deal with fellow Indian drug maker Dr. Reddy's Laboratories Ltd.
J&J Expands Russian OTC Foothold Via J.B. Chemicals Portfolio Acquisition
Johnson & Johnson expands its consumer health presence in Russia and other Eastern European markets with the acquisition of several OTC brands from J.B. Chemicals & Pharmaceuticals
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.